Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus. 1992

A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
Department of Medicine, All India Institute of Medical Sciences, New Delhi.

To determine the efficacy and safety of intermittent intravenous pulse cyclophosphamide in patients of severe systemic lupus erythematosus (SLE), 50 patients having severe/refractory lupus nephritis, vasculitis or neuropsychiatric manifestations were treated with 3 weekly pulses of cyclophosphamide for 6 such pulses. This treatment was found to be associated with significant and sustained improvement during a 2 yr follow up with respect to the mean renal activity score, individual renal parameters (proteinuria, erythrocyturia, and serum creatinine levels), focal neurological manifestations, vasculitic lesions, antinuclear antibody titers, complement component C3, anti-dsDNA antibodies levels and ESR. There was a sustained decrease in the overall mean disease activity score, and the mean daily dose of prednisolone (pretreatment 32.62 mg daily to 3.75 mg daily after 24 months). There was a significant decline in the percentage and absolute B cell count after 7, 14 and 21 days of this treatment. Effect on other lymphocyte subsets (CD3+, CD4+ and CD8+) was not marked. Pulse cyclophosphamide could therefore be an effective and less toxic form of treatment in patients with SLE having severe lupus nephritis, focal neurological lesions or vasculitis.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
January 1999, Lijecnicki vjesnik,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
January 1996, Nephron,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
January 2013, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
February 1996, Lupus,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
August 1998, Ryumachi. [Rheumatism],
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
January 1992, Contributions to nephrology,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
June 1994, Ryumachi. [Rheumatism],
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
May 1993, Arthritis and rheumatism,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
January 1996, Clinical and experimental rheumatology,
A N Malaviya, and R R Singh, and R Sindhwani, and Y N Singh, and R K Ahujà, and U N Bhuyan, and S D Khare, and A Kumar, and R Malaviya, and P C Negi
July 2015, Lupus,
Copied contents to your clipboard!